Sideroblastic Anemias Treatment & Management
- Author: Muhammad A Mir, MD, FACP; Chief Editor: Emmanuel C Besa, MD more...
Treatment of sideroblastic anemia may include removal of toxic agents; administration of pyridoxine, thiamine, or folic acid; transfusion (along with antidotes if iron overload develops from transfusion); other medical measures; or bone marrow or liver transplantation.
Admission and inpatient care may be needed for patients with sideroblastic anemia and cirrhosis, as well as those who have need of repeated blood transfusions.
Removal of Toxic Agents
Toxic agents such as zinc, lead, and drugs such as penicillamine should be removed whenever possible; however, this may not always be easy. For example, isoniazid is the mainstay of treatment of active tuberculosis, and a risk-benefit analysis is essential for each patient.
Vitamin B Therapy
Pyridoxine (vitamin B-6) deserves a trial in all cases of sideroblastic anemia as many acquired and certain congenital forms of sideroblastic anemia respond to this relatively safe drug. The response will be evident in a few weeks with reticulocytosis and improving hemoglobin levels.
The dose should be tailored to the patient’s tolerance. Dosages up to 1 g/day have been used, but the goal is to find a dosage of pyridoxine (usually 50-200 mg/d) that will maintain the hemoglobin level and yet prevent toxicity (peripheral neuropathy). For those whose condition responds, treatment is life long.
Pyridoxal 5′ phosphate (PLP) is an active form of pyridoxine that has been successfully used in the treatment of sideroblastic anemias in some patients who do not respond to pyridoxine.
Thiamine (vitamin B-1) works by an incompletely understood mechanism to correct sideroblastic anemia in DIDMOAD syndrome.
Folic acid has been reported to reverse sideroblastic changes by itself in some patients. It is advisable to replace folate in pyridoxine-responsive cases to ensure adequate supplies of ingredients during a period of increased hemoglobin synthesis.
Transfusion is the mainstay of treatment for those whose sideroblastic anemia does not respond to pyridoxine therapy. It is problematic and should be avoided if the anemia is mild to moderate and the patient asymptomatic.
Even in the absence of transfusion, patients with sideroblastic anemia are prone to develop iron overload. Transfusion in sideroblastic anemia has been known to worsen iron overload and lead to secondary hemochromatosis and cirrhosis. Iron overload in sideroblastic anemia can be fatal.
Management of iron overload
Deferoxamine (desferrioxamine; Desferal) can be used if iron overload develops from repeated blood transfusions. Although effective, it must be administered by a subcutaneous pump for several hours a day.
Deferasirox (Exjade) is a relatively new oral iron chelator that has been used instead of deferoxamine and appears to be effective. First used in Europe, it has been introduced in United States and is a once-daily pill. Renal toxicity and allergic reactions are a concern.
Phlebotomy can be performed for iron overload. In some patients who do not tolerate deferoxamine therapy, this procedure is an option, but the limiting factor may be anemia.
Heme arginate as an infusion has been used with mixed results and is not a first-line drug.
Erythropoietin (EPO) has been tried and does not appear to reverse sideroblastic anemia ; it has also been reported to cause neutropenia in this setting. EPO in combination with G-CSF appears to have a better response rate than EPO alone (50%).[81, 82]
Lenalidomide may reduce transfusion needs in some patients with EPO-refractory RARS.
Prednisone and danazol have not been effective, except for some patients with active connective tissue disease (eg, systemic lupus erythematosus (SLE), ) in whom sideroblastic changes disappear with prednisone when the SLE flare subsides.
Cytotoxic therapies such as cyclophosphamide have been tried with some success in patients with erythropoietin inhibitors, resulting in ineffective erythropoiesis.
Chloroquine has been successfully used to treat pyridoxine-resistant sideroblastic anemia, but no large study has been done, and thus only limited data are available. The drug affects heme metabolism and is also used in certain porphyrias.
Ubidecarenone (coenzyme-Q10) has been used with mixed results in the treatment of sideroblastic anemia and is not recommended as standard of care.[88, 89]
Azacitidine and other newer agents being used for myelodysplastic syndrome (MDS) have not been specifically studied or approved for sideroblastic anemias in general.
Bone marrow transplantation is a treatment of last resort and is best saved for young patients whose conditions are pyridoxine resistant and transfusion dependent and who have a human leukocyte antigen (HLA)-matched sibling. Even then, the response ranges from cure to death within weeks. Severe graft versus host disease has been reported even with HLA-identical sibling donors. The evidence is limited to a few case reports in the literature.[92, 93, 94]
Surgical intervention in cases of sideroblastic anemia may include liver transplantation for cirrhosis and iron overload that is not responsive to chelation and phlebotomy.
Dietary Measures and Activity Restriction
Dietary restrictions in cases of sideroblastic anemia include the following:
Avoidance of zinc-containing supplements
Avoidance of alcohol
Activity is as tolerated in patients with sideroblastic anemia.
Consultations and Long-Term Monitoring
Transfer to the care of a hematologist is recommended, especially for cases of pyridoxine-resistant sideroblastic anemia and for patients who become transfusion dependent.
Consider consultations with the following in cases of sideroblastic anemia:
A neurologist (in mitochondrial myopathy-anemia syndromes)
Regular follow-up is essential, even for patients with sideroblastic anemia whose condition responds to therapy.
Acute idiopathic sideroblastic anemia, refractory anemia with ring sideroblasts (RARS) or MDS must be monitored for potential transformation into acute leukemias.
Harris JW. X-linked, pyridoxine-responsive sideroblastic anemia. N Engl J Med. 1994 Mar 10. 330(10):709-11. [Medline].
Takeda Y, Sawada H, Tashima M, Okuma M, Kondo M. Erythropoietic protoporphyria without cutaneous photosensitivity and with ringed sideroblasts in an atomic bomb survivor. Lancet. 1996 Feb 10. 347(8998):395-6. [Medline].
Rademakers LH, Koningsberger JC, Sorber CW, et al. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest. 1993 Feb. 23(2):130-8. [Medline].
Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y, et al. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol. 2013 Jan. 92(1):1-9. [Medline]. [Full Text].
Cotter PD, Baumann M, Bishop DF. Enzymatic defect in "X-linked" sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci U S A. 1992 May 1. 89(9):4028-32. [Medline]. [Full Text].
Harigae H, Furuyama K. Hereditary sideroblastic anemia: pathophysiology and gene mutations. Int J Hematol. 2010 Oct. 92(3):425-31. [Medline].
Csere P, Lill R, Kispal G. Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p. FEBS Lett. 1998 Dec 18. 441(2):266-70. [Medline].
Shimada Y, Okuno S, Kawai A, et al. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J Hum Genet. 1998. 43(2):115-22. [Medline].
Zeharia A, Fischel-Ghodsian N, Casas K, et al. Mitochondrial myopathy, sideroblastic anemia, and lactic acidosis: an autosomal recessive syndrome in Persian Jews caused by a mutation in the PUS1 gene. J Child Neurol. 2005 May. 20(5):449-52. [Medline].
Bottomley SS. Sideroblastic anemias. Lee GR, Foerster J, Lukens J, et al, eds. Wintrobe's Clinical Hematology. 10th ed. Baltimore, Md: Lippincott, Williams & Wilkins; 1999. Vol 1: 1022-46.
Pearson HA, Lobel JS, Kocoshis SA, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr. 1979 Dec. 95(6):976-84. [Medline].
O'Grady MJ, Monavari AA, Cotter M, Murphy NP. Sideroblastic anaemia and primary adrenal insufficiency due to a mitochondrial respiratory chain disorder in the absence of mtDNA deletion. BMJ Case Rep. 2015 Feb 26. 2015:[Medline].
Borgna-Pignatti C, Marradi P, Pinelli L, Monetti N, Patrini C. Thiamine-responsive anemia in DIDMOAD syndrome. J Pediatr. 1989 Mar. 114(3):405-10. [Medline].
Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol. 2015 Jun. 90 (6):549-59. [Medline].
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30. 114(5):937-51. [Medline].
Hellström-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program. 2008. 52-9. [Medline].
Gattermann N. SF3B1 and the riddle of the ring sideroblast. Blood. 2012 Oct 18. 120(16):3167-8. [Medline].
Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013 Jan 10. 121(2):260-9. [Medline].
Vandermolen L, Rice L, Rose MA, Lynch EC. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors. Arch Intern Med. 1988 Mar. 148(3):653-6. [Medline].
Miki H, Kuwayama Y, Hara T, et al. [Copper deficiency with pancytopenia, bradycardia and neurologic symptoms] [Japanese]. Rinsho Ketsueki. 2007 Mar. 48(3):212-6. [Medline].
Niel O, Thouret MC, Bérard E. Anemia in congenital nephrotic syndrome: role of urinary copper and ceruloplasmin loss. Blood. 2011 Jun 2. 117(22):6054-5. [Medline].
Prodan CI, Bottomley SS, Vincent AS, Cowan LD, Greenwood-Van Meerveld B, Holland NR, et al. Copper deficiency after gastric surgery: a reason for caution. Am J Med Sci. 2009 Apr. 337(4):256-8. [Medline].
Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005 Jan. 123(1):125-31. [Medline].
Kumar N, Elliott MA, Hoyer JD, et al. "Myelodysplasia," myeloneuropathy, and copper deficiency. Mayo Clin Proc. 2005 Jul. 80(7):943-6. [Medline].
Champe PC, Harvey RA. Conversion of amino acids to specialized products. Biochemistry. 2nd ed. Philadelphia, Pa: JB Lippincott Co; 1994. 259.
Lubran MM. Lead toxicity and heme biosynthesis. Ann Clin Lab Sci. 1980 Sep-Oct. 10(5):402-13. [Medline].
Scharf RE, Aul C. [Alcohol-induced disorders of the hematopoietic system] [German]. Z Gastroenterol. 1988 Oct. 26 suppl 3:75-83. [Medline].
Homann C, Hasselbalch HC. [Hematological abnormalities in alcoholism] [Danish]. Ugeskr Laeger. 1992 Aug 3. 154(32):2184-7. [Medline].
Conso F, Tulliez M, Fauvarques MO, Nenna AD. [Sideroblastic anemia, lead poisoning and wine from Bordeaux] [French]. Ann Med Interne (Paris). 1984. 135(1):43-5. [Medline].
McColl KE, Moore MR, Thompson GG, Goldberg A. Abnormal haem biosynthesis in chronic alcoholics. Eur J Clin Invest. 1981 Dec. 11(6):461-8. [Medline].
Del Favero H, Grebe G, Lira P, Mezzano D. [Chloramphenicol induced sideroblastic anemia (author's transl)] [Spanish]. Rev Med Chil. 1977 Jun. 105(6):384-7. [Medline].
Vial T, Grignon M, Daumont M, et al. Sideroblastic anaemia during fusidic acid treatment. Eur J Haematol. 2004 May. 72(5):358-60. [Medline].
Montpetit MC, Shammo JL, Loew J, et al. Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device. J Heart Lung Transplant. 2004 Sep. 23(9):1119-22. [Medline].
Rudek MA, Horne M, Figg WD, et al. Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. Am J Hematol. 2001 May. 67(1):51-3. [Medline].
Yoshimoto S, Takeuchi M, Tada A. [Secondary sideroblastic anemia caused by long term administration of anti-tuberculous agents including isoniazid] [Japanese]. Rinsho Ketsueki. 1992 Jul. 33(7):986-90. [Medline].
Brodsky RA, Hasegawa S, Fibach E, et al. Acquired sideroblastic anaemia following progesterone therapy. Br J Haematol. 1994 Aug. 87(4):859-62. [Medline].
Popovic K, Stanulovic D, Stanulovic M. Sideroblastic anemia in chronic phenacetin misuse. Clin Toxicol. 1973. 6(4):585-98. [Medline].
Perry AR, Pagliuca A, Fitzsimons EJ, Mufti GJ, Williams R. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol. 1996 Jul. 64(1):69-72. [Medline].
Magalhães SM, Duarte FB, Ribeiro SC, Borovik CL, Lorand-Metze I. Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan. Leukemia. 2000 Jan. 14(1):214-5. [Medline].
Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol. 2000 Mar. 108(4):724-8. [Medline].
O'Brien H, Amess JA, Mollin DL. Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia. Br J Haematol. 1982 Jul. 51(3):451-6. [Medline].
Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009 Jun. 41(6):651-3. [Medline].
Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12. 119(2):569-72. [Medline].
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 Sep 11. 478(7367):64-9. [Medline].
Yang J, Qian J, Lin J, Yang XF, Qian W, Chen Q, et al. Development of a High-Resolution Melting Analysis for the Detection of the SF3B1 Mutations. Genet Test Mol Biomarkers. 2013 Feb 7. [Medline].
Farhi DC, Luebbers EL, Rosenthal NS. Bone marrow biopsy findings in childhood anemia: prevalence of transient erythroblastopenia of childhood. Arch Pathol Lab Med. 1998 Jul. 122(7):638-41. [Medline].
Juneja SK, Imbert M, Sigaux F, Jouault H, Sultan C. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol. 1983 May. 36(5):566-9. [Medline]. [Full Text].
Bain BJ. The bone marrow aspirate of healthy subjects. Br J Haematol. 1996 Jul. 94(1):206-9. [Medline].
Hadnagy C. Primary acquired sideroblastic anemia and myelodysplastic syndrome from a geriatric point of view. Z Gerontol. 1991 Mar-Apr. 24(2):105-9. [Medline].
Impey L, Greenwood C, Taylor A, Redman C, Wainscoat J. Recurrent acquired sideroblastic anemia in a twin pregnancy. J Matern Fetal Med. 2000 Jul-Aug. 9(4):248-9. [Medline].
Linker CA. Blood. McPhee SJ, Papadakis MA, Tierney LM, eds. Current Medical Diagnosis and Treatment. 45th ed. New York, NY: McGraw Hill; 2006. 486.
Garand R, Gardais J, Bizet M, et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res. 1992. 16(5):463-8. [Medline].
Cheng DS, Kushner JP, Wintrobe MM. Idiopathic refractory sideroblastic anemia: incidence and risk factors for leukemic transformation. Cancer. 1979 Aug. 44(2):724-31. [Medline].
May A, Fitzsimons E. Sideroblastic anaemia. Baillieres Clin Haematol. 1994 Dec. 7(4):851-79. [Medline].
Kumar A, Jazieh AR. Case report of sideroblastic anemia caused by ingestion of coins. Am J Hematol. 2001 Feb. 66(2):126-9. [Medline].
Cotter PD, May A, Fitzsimons EJ, Houston T, Woodcock BE, al-Sabah AI, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995 Oct. 96(4):2090-6. [Medline]. [Full Text].
Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood. 1997 Dec 15. 90(12):4961-72. [Medline]. [Full Text].
Tuckfield A, Ratnaike S, Hussein S, Metz J. A novel form of hereditary sideroblastic anaemia with macrocytosis. Br J Haematol. 1997 May. 97(2):279-85. [Medline].
Dorland's Illustrated Medical Dictionary. 30th ed. Philadelphia, Pa: WB Saunders; 2004.
Lazarchick J. Basophilic stippling - lead poisoning. American Society of Hematology image bank. Available at http://ashimagebank.hematologylibrary.org/cgi/content/full/2004/0621/101136. Accessed: October 23, 2008.
Stavem P, Rørvik TO, Rootwelt K, Josefsen JO. Severe iron deficiency causing loss of ring sideroblasts. Scand J Haematol. 1983 Oct. 31(4):389-91. [Medline].
Bisp MR, Bor MV, Heinsvig EM, Kall MA, Nexø E. Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay. Anal Biochem. 2002 Jun 1. 305(1):82-9. [Medline].
Greenberg PL, Attar E, Battiwalla M, et al, for the NCCN Myelodysplastic Panel. NCCN clinical practice guidelines in oncology. Myelodysplastic syndromes. v2. 2008. Available at http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed: December 6, 2007.
Koc S, Harris JW. Sideroblastic anemias: variations on imprecision in diagnostic criteria, proposal for an extended classification of sideroblastic anemias. Am J Hematol. 1998 Jan. 57(1):1-6. [Medline]. [Full Text].
Sztern B, de Saint-Georges A, Telerman A, Lustman F. [Major sideroblastosis corrected by simple administration of folates] [French]. Presse Med. 1984 Jul 14-21. 13(29):1789. [Medline].
Abadia R, Rochant H, Levy VG. [Hemochromatotic cirrhosis complicating pyridoxine-sensitive hereditary sideroblastic anemia. Case report] [French]. Ann Med Interne (Paris). 1983. 134(4):327-32. [Medline].
Bottomley SS. Sideroblastic anemia: death from iron overload. Hosp Pract (Off Ed). 1991 Apr. 26 Suppl 3:55-6. [Medline].
Zoller WG, Hehlmann R. Sideroachrestic anemia with iron loading: treatment with desferrioxamine. Klin Wochenschr. 1986 May 2. 64(9):417-22. [Medline].
French TJ, Jacobs P. Sideroblastic anaemia associated with iron overload treated by repeated phlebotomy. S Afr Med J. 1976 Apr 3. 50(15):594-6. [Medline].
Volin L. Haem arginate treatment for hereditary sideroblastic anaemia. Eur J Haematol. 1989 Jan. 42(1):60-6. [Medline].
Ljung T, Bäck R, Hellström-Lindberg E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. Haematologica. 2004 Dec. 89(12):1446-53. [Medline]. [Full Text].
Benzadón RJ, Gurfinkel EP. [Neutropenia and hypotension during treatment with recombinant human erythropoietin in refractory anemia with ring sideroblasts] [Spanish]. Sangre (Barc). 1990 Jun. 35(3):238-9. [Medline].
Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008 Jul 20. 26(21):3607-13. [Medline].
Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia. 2006 Jul. 20(7):1319-21. [Medline].
Huls G, Mulder AB, Rosati S, van de Loosdrecht AA, Vellenga E, de Wolf JT. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood. 2010 Jul 15. 116(2):180-2. [Medline].
Doll DC, Ringenberg QS, Yarbro JW. Danazol therapy in acquired idiopathic sideroblastic anemia. Acta Haematol. 1987. 77(3):170-1. [Medline].
Jiménez-Balderas FJ, Morales-Polanco MR, Gutierrez L. Acute sideroblastic anemia in active systemic lupus erythematosus. Lupus. 1994 Jun. 3(3):157-9. [Medline].
Drénou B, Guyader D, Turlin B, Fauchet R. Treatment of sideroblastic anemia with chloroquine. N Engl J Med. 1995 Mar 2. 332(9):614. [Medline].
Gattermann N, Briviba K, Tsamaloukas A, Aul C, Schneider W. No improvement of refractory sideroblastic anaemia with ubidecarenone. Lancet. 1995 Apr 29. 345(8957):1121-2. [Medline].
García Silva MT, Izquierdo Martinez M, Beloqui Ruiz O. Improvement of refractory sideroblastic anaemia with ubidecarenone. Lancet. 1994 Apr 23. 343(8904):1039. [Medline].
Urban C, Binder B, Hauer C, Lanzer G. Congenital sideroblastic anemia successfully treated by allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992 Oct. 10(4):373-5. [Medline].
González MI, Caballero D, Vázquez L, et al. Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. Br J Haematol. 2000 Jun. 109(3):658-60. [Medline].
Ayas M, Al-Jefri A, Mustafa MM, et al. Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation. Br J Haematol. 2001 Jun. 113(4):938-9. [Medline].
Kook H, Kim CJ, Yoon WS, Ryang DW, Hwang TJ. Successful allogeneic bone marrow transplantation for childhood-onset refractory anemia with ringed sideroblasts. J Korean Med Sci. 2000 Feb. 15(1):103-4. [Medline]. [Full Text].
Medeiros BC, Kolhouse JF, Cagnoni PJ, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone Marrow Transplant. 2003 Jun. 31(11):1053-5. [Medline]. [Full Text].
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct 13. 365(15):1384-95. [Medline]. [Full Text].
Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol. 2005 Oct. 131(2):180-4. [Medline].